Stock Eyeing 261% Growth This Year Sets Up New Buy Point

After delivering 150% earnings growth last quarter, Wall Street estimates call for diabetes management leader Insulet (PODD) to post a 261% EPS spike for the full year. That has PODD stock setting up a new buy point.X Based in Massachusetts and founded in 2000, the innovative medical device firm…#meritmedicalsystems #abmd #massachusetts #omnipod5automatedinsulindeliverysys #eps #johnsonjohnson #csmrratinginsulet #dexcom #insuletindemandwithinstrongindustry #meritmedical
Source: Reuters: Health - Category: Consumer Health News Source Type: news